<?xml version="1.0" encoding="UTF-8"?>
<p>On the other hand, human monoclonal antibodies or their fragments developed in the lab have shown encouraging results as well. Tian et al. confirmed the binding of a human monoclonal antibody CR3022 to the receptor-binding domain (RBD) of 2019-nCoV with high affinity [
 <xref rid="B214" ref-type="bibr">214</xref>], highlighting the therapeutic potential of CR3022 toward COVID-19, though further 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> studies are required before it could be used clinically.
</p>
